MenoGeniX is a privately held, phase II clinical‐stage biotech company developing MNGX‐100 to treat hot flashes and related vasomotor symptoms of menopause. MNGX-100 is based on an FDA-approved biologic that MenoGeniX is repurposing as an alternative to the only other approved therapies for hot flashes, namely estrogen-containing hormone therapy and a low dose form of the anti-depressant paroxetine. MenoGeniX looks forward to providing a needed alternative to the currently approved therapies for women undergoing the menopause transition.
Debra M. Duke
President & CEO
12635 East Montview Blvd., Suite 100
Aurora, Colorado, USA 80045
Mobile: +1 303.995.7979